Back to School: How biopharma can reboot drug development. Access exclusive analysis here

tgAAVCF: Phase II

Final results from a double-blind, placebo-controlled Phase II trial in 37 patients showed that tgAAVCF

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE